Compound primer
Retatrutide — research primer (lab procurement)
RUO — Research / laboratory use only. Not for human or veterinary use. Not a drug, food, or cosmetic. No claims of safety or efficacy for human use.
Short compound primer for Canadian laboratory procurement. Aligns with the Pharmaceutical Peptides research brief (CAS, stocked strengths, PubMed). This is literature context for the bench — not a clinical protocol, dosing schedule, or wellness claim.
Identifiers
Name
Retatrutide
Also known as
LY3437943
CAS
2381089-83-2
Research class
Unimolecular triple agonist (GLP-1 / GIP / glucagon receptors)
Presentation
Lyophilized vial
Stocked strengths
10 mg · 20 mg · 30 mg vials (pricing on request)
Mechanism (lab frame)
Retatrutide is studied as a single peptide that engages GLP-1, GIP, and glucagon receptors. Published work examines metabolic and energy-balance pathways in controlled research settings. Use this summary only to place the compound in the literature — not to design human administration.
Selected literature (PubMed)
- Coskun et al., Cell Metabolism 2022 — LY3437943 discovery / proof-of-concept. PMID 35985340
- Jastreboff et al., NEJM 2023 — Phase 2 triple-agonist clinical study (literature reference). PMID 37366315
Cite the primary papers for protocol design in your own IRB / lab approvals. Do not treat trial publications as supplier use instructions.
Bench notes (process only)
- Receiving: Match vial lot to lot-matched COA (HPLC purity + MS identity).
- Storage (lyophilized): Follow the COA (typically refrigerated; protect from light and moisture).
- After reconstitution: Aliquot per your lab SOP; do not assume multi-week stability without your own validation.
- Notebook: Record lot, date, solvent, target concentration, and operator. Example dilution math for research prep (not human dosing): label mg ÷ target mg/mL = diluent mL.
No syringe charts, bodyweight tables, or injection how-tos are provided or supported.
COA / lot
Current lots available on request. Every shipment can include a lot-matched COA. For Canadian buyers, request domestic fulfillment and archive COA + invoice # with your RUO attestation (see the Canada research-peptide procurement checklist). How to read HPLC + MS is in How to read a peptide COA.
Lab FAQ
What strengths are stocked, and can you quote N of each with COA?
10 / 20 / 30 mg. Email quantities per strength — we return pricing and a COA pack.
Is this for human use?
No. Research / laboratory use only.
Sources
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist… Cell Metab. 2022. PMID 35985340.
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315.
- Public research brief: /research/retatrutide/ (CAS 2381089-83-2; PMIDs 35985340 and 37366315).
Email request@
request@pharmapeptidesrx.com — retatrutide, strength(s), and quantity. Reply includes pricing and a lot-matched COA for laboratory research use only.
Pharmaceutical Peptides · www.pharmapeptidesrx.com
RUO. Research use only. Not for human or veterinary use.